Journal of Cancer Research and Therapeutics Close
 

Figure 5: Rank Probabilities Plot of effect of Monoclonal Antibody Check Point Inhibitors on survival given 2nd line in Nonsmall cell lung cancer. (a) Check point inhibitors and 2nd line overall survival, (b) Check point inhibitors and 2nd line progression-free survival (Che=Chemotherapy, Pem=Pembrolizumab, Pem (h)=Pembrolizumab high dose, Niv=Nivolumab, Ave=Avelumab, Ate=Atezolizumab. Higher rank numbers imply higher efficacy)

Figure 5: Rank Probabilities Plot of effect of Monoclonal Antibody Check Point Inhibitors on survival given 2<sup>nd</sup> line in Nonsmall cell lung cancer. (a) Check point inhibitors and 2<sup>nd</sup> line overall survival, (b) Check point inhibitors and 2<sup>nd</sup> line progression-free survival (Che=Chemotherapy, Pem=Pembrolizumab, Pem (h)=Pembrolizumab high dose, Niv=Nivolumab, Ave=Avelumab, Ate=Atezolizumab. Higher rank numbers imply higher efficacy)